Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4168 - Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States

Date

11 Sep 2017

Session

Poster display session

Presenters

Sacha Satram-Hoang

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

S. Satram-Hoang1, P. Bajaj2, A. Stein2, K.Q. Hoang1, F. Momin1, P. Cortazar2, C. Reyes2

Author affiliations

  • 1 Department Of Epidemiology, Q.D. Research, Inc., 95746 - Granite Bay/US
  • 2 Us Medical Affairs, Genentech Inc., 94080 - South San Francisco/US
More

Resources

Abstract 4168

Background

Triple negative breast cancer (TNBC) is more aggressive than other breast cancer (BC) subtypes and accounts for up to 20% of all BC. Despite the poorer prognosis, there are no approved targeted treatments available and chemotherapy (chemo) remains the only choice. We examined treatment patterns and outcomes among elderly metastatic TNBC patients (pts) in routine clinical practice.

Methods

Patients were identified from the linked SEER-Medicare database (1/1/2001-12/31/2013). The analysis included TNBC de novo Stage IV pts (n = 776) and pts with distant recurrences following an initial diagnosis of Stage I-III (n = 1851). Pts were ≥66 years and continuously enrolled in Medicare Parts A/B in the year prior to diagnosis. The analysis was stratified by age

Results

The mean age at metastatic diagnosis was 77.6 years and 1259 (48%) pts received treatment with chemo. Compared to 

Conclusions

In this real-world analysis, 52% of elderly TNBC pts did not receive chemo following their metastatic diagnosis. Although the survival benefits of chemo were stronger in the younger cohort, the benefits of treatment were maintained among ≥70 year olds who were also less likely to receive chemo. These findings suggest opportunities exist to improve the clinical treatment of elderly TNBC pts.

Clinical trial identification

Legal entity responsible for the study

Q.D. Research, Inc

Funding

Genentech, Inc.

Disclosure

S. Satram-Hoang, K.Q. Hoang, F. Momin: Research funding to Institution from Genentech. P. Bajaj, A. Stein, P. Cortazar, C. Reyes: Genenetech employment and Roche stock ownership.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.